antisens
molecul
readili
cross
cell
membran
limit
use
antisens
system
techniqu
work
introduc
molecul
cell
embryo
cell
cultur
uncharg
antisens
bear
group
guanidinium
moieti
either
linear
peptid
dendrim
scaffold
enter
cell
endocytosi
subsequ
escap
endosom
cytosolnuclear
compart
cell
technolog
allow
system
administr
antisens
make
gene
knockdown
splice
modif
feasibl
adult
anim
review
present
exampl
anim
studi
techniqu
develop
ppmo
argininerich
cellpenetr
peptid
link
morpholino
oligo
also
perform
use
commerci
avail
vivomorpholino
eight
guanidinium
group
dendrimer
scaffold
link
morpholino
oligo
antisensebas
techniqu
block
translat
modifi
premrna
splice
inhibit
mirna
matur
inhibit
viral
replic
conveni
appli
adult
anim
inject
ppmo
vivomorpholino
morpholino
oligo
stericblock
antisens
molecul
bind
rna
get
way
cellular
process
oligo
electr
charg
interact
strongli
protein
requir
activ
rnaseh
argonaut
catalyt
protein
activ
antisens
molecul
howev
readili
cross
cell
membran
without
deliveri
techniqu
prevent
effect
use
adult
anim
deliveri
morpholino
oligo
achiev
vivo
vivomorpholino
morpholino
oligo
link
argininerich
cell
penetr
peptid
ppmo
longstand
barrier
appli
morpholino
antisens
techniqu
adult
anim
overcom
vivomorpholino
ppmo
enter
cell
extracellular
space
gain
access
cytosol
nuclear
compart
antisens
effect
observ
system
deliveri
vivomorpholino
ppmo
effect
techniqu
deliv
oligo
cytosol
nuclear
compart
tissu
cultur
develop
mechan
scrape
electropor
use
endosom
escap
reagent
unmodifi
morpholino
use
routin
block
translat
modifi
splice
inhibit
mirna
activ
inhibit
viral
replic
well
exot
rnablock
applic
morpholino
antisens
structur
type
revolutionari
tool
development
biolog
success
embryo
came
microinject
morpholino
oligo
egg
singl
cell
zygot
cell
divis
morpholino
apport
daughter
cell
neatli
avoid
problem
deliv
antisens
separ
cell
manycel
organ
addit
use
determin
gene
function
interact
embryo
morpholino
antisens
oligo
use
research
broad
rang
diseas
well
sever
clinic
trial
avi
biopharma
inc
case
carri
work
research
therapeut
applic
unmodifi
morpholino
oligo
limit
difficulti
vivo
deliveri
howev
deliveri
rel
high
dose
unmodifi
morpholino
dystroph
muscl
anim
model
dmd
induc
express
function
dystrophin
skelet
muscl
unmodifi
morpholino
current
clinic
trial
treatment
dmd
http
morpholino
oligo
manufactur
ribosid
ribos
ring
open
oxid
reclos
ammonia
product
subsequ
reduc
substitut
morpholin
base
morpholin
nitrogen
protect
subunit
activ
dimethylamino
phosphorodichlorid
activ
subunit
ad
synthesi
resin
wash
deprotect
activ
step
activ
base
ad
oligo
cleav
resin
deprotect
ammonium
hydroxid
purifi
quantit
often
follow
lyophil
steril
substitut
peptid
dendrim
scaffold
guanidinium
may
ad
morpholin
nitrogen
oligo
still
attach
synthesi
resin
altern
peptid
may
ad
solut
phase
resin
cleavag
purif
step
end
morpholino
oligo
describ
label
refer
properli
number
atom
morpholino
backbon
instead
atom
design
natur
nucleic
acid
use
analog
label
morpholino
end
nucleic
acid
hydroxyl
often
phosphoryl
one
end
hydroxyl
end
methylen
attach
morpholin
ring
design
end
morpholino
subunit
morpholin
nitrogen
design
end
nomenclatur
chosen
order
make
design
direct
along
morpholino
oligo
familiar
molecular
biologist
accustom
refer
end
rna
dna
unmodifi
morpholino
oligo
endocytos
littl
activ
rna
target
uptak
endocytosi
mean
antisens
oligo
reach
cytoplasm
nucleu
cell
fluorescentlylabel
morpholino
detect
dim
punctuat
fluoresc
within
endosom
cell
littl
antisens
escap
endosom
cytosolnuclear
compart
biolog
activ
morpholino
degrad
endosom
remain
trap
mani
biolog
problem
best
studi
adult
method
allow
entri
antisens
cell
adult
organ
desir
ideal
system
deliveri
could
accomplish
routin
mean
intraven
intraperiton
inject
technolog
allow
enough
endocytos
oligo
escap
endosom
biolog
activ
would
enabl
vivo
deliveri
oligo
administ
system
inject
technolog
develop
ppmo
vivomorpholino
ppmo
may
argininerich
cellpenetr
peptid
link
either
end
end
morpholino
oligo
arginin
guanidinium
moieti
part
side
chain
presenc
guanidinium
shown
increas
cellular
uptak
conjug
materi
studi
mechan
ppmo
entri
shown
cellpenetr
peptid
offer
two
advantag
unmodifi
morpholino
enhanc
uptak
endosom
critic
enhanc
ensodom
escap
vivomorpholino
octaguanidinium
dendrim
construct
end
morpholino
oligo
figur
first
effect
chemicallymedi
method
system
deliveri
morpholino
antisens
base
coval
link
oligo
cellpenetr
peptid
use
argininerich
cellpenetr
peptid
deliv
uncharg
antisens
molecul
molecul
call
peptidelink
phosphorodiamid
morpholino
oligom
ppmo
short
research
develop
safe
effect
peptid
sequenc
ppmo
focu
hong
moulton
group
avi
biopharma
inc
preclin
work
ppmo
duchenn
muscular
dystrophi
current
ongo
studi
ppmo
shown
uptak
oligo
energydepend
temperaturedepend
process
prevent
use
endocytosi
inhibitor
characterist
indic
uptak
ppmo
endocytosi
fraction
endocytos
ppmo
escap
endosom
enter
cytosol
nuclear
compart
block
mrna
translat
modifi
premrna
splice
intraven
inject
intraperiton
inject
intranas
administr
ppmo
mice
inhibit
viral
replic
inject
ppmo
transgen
mice
carri
engin
splicereport
gene
trigger
express
green
fluoresc
protein
throughout
tissu
positivelycharg
arginin
amino
acid
residu
electrostat
attract
uncharg
antisens
morpholino
oligo
peptid
nucleic
acid
pna
oligo
posit
charg
arginin
free
interact
membran
end
arginin
amino
acid
side
chain
guanidinium
group
carri
amino
acid
posit
charg
charg
guanidinium
group
attract
phosphat
phosphat
neg
charg
also
form
two
hydrogen
bond
phosphat
oxygen
make
attract
guanidinium
phosphat
unusu
strong
noncoval
interact
may
strong
interact
distort
endosom
membran
render
permeabl
vivomorpholino
morpholino
antisens
oligo
coval
link
molecular
scaffold
carri
guanidinium
group
eight
tip
customsequ
antisens
molecul
enabl
morpholino
applic
adult
anim
vivomorpholino
shown
effect
mice
test
rat
adult
zebrafish
variou
organ
explant
make
vivomorpholino
scaffold
hold
guanidinium
group
ad
morpholin
nitrogen
morpholino
oligo
oligo
still
bound
end
synthesi
resin
subsequ
treatment
ammonia
cleav
vivomorpholino
synthesi
resin
deprotect
morpholino
base
deprotect
eight
tip
scaffold
next
treatment
omethyl
isourea
convert
eight
termin
amino
group
guanidinium
group
morpholino
oligo
bind
complementari
rna
molecular
process
normal
occur
site
morpholino
bound
rna
morpholino
might
suitabl
posit
get
way
process
prevent
occur
mechan
call
steric
block
effect
morpholino
cell
depend
morpholino
bind
rna
determin
whether
block
process
process
block
three
common
applic
morpholino
oligo
block
translat
mrna
modifi
splice
premrna
inhibit
mirna
activ
addit
work
done
viral
target
intern
ribosom
entri
site
cycliz
sequenc
much
report
work
ppmo
involv
viral
target
exot
target
also
explor
bind
slipperi
site
trigger
ribosom
frameshift
bind
ribozym
prevent
catalyt
cleavag
rna
translat
block
simplest
method
knock
gene
express
morpholino
make
protein
capdepend
translat
small
subunit
ribosom
bind
cap
mrna
along
protein
form
initi
complex
initi
complex
move
along
untransl
region
utr
mrna
start
codon
reach
start
codon
larg
subunit
ribosom
dock
small
ribosom
subunit
process
begin
link
togeth
amino
acid
form
new
protein
morpholino
block
journey
ribosom
initi
complex
start
codon
halt
translat
mrna
link
amino
acid
start
morpholino
bind
rna
target
anywher
start
code
region
long
oligo
bind
onto
start
codon
upstream
direct
start
codon
activ
translat
block
oligo
assay
immunochem
method
typic
western
blot
halt
translat
protein
immedi
caus
detect
chang
protein
signal
western
blot
preexist
protein
must
degrad
time
protein
signal
decreas
time
need
knockdown
assay
vari
protein
differ
protein
differ
stabil
cell
premrna
transcrib
dna
templat
goe
process
nucleu
form
matur
mrna
process
typic
includ
ad
cap
splice
intron
ligat
togeth
exon
ad
polya
tail
splice
modif
involv
bind
morpholino
target
premrna
unsplic
mrna
redirect
spliceosom
new
pattern
splice
produc
matur
mrna
sequenc
differ
sequenc
produc
absenc
morpholino
usual
morpholino
bound
mostlyintron
target
boundari
exon
intron
target
prevent
bind
molecul
direct
spliceosom
splice
site
typic
result
splice
modif
includ
remov
target
exon
inclus
first
last
intron
matur
mrna
anoth
class
target
consist
bind
site
rna
spliceregul
protein
normal
bind
exon
splice
enhanc
intron
splice
suppressor
protein
import
direct
altern
splice
natur
process
cell
make
altern
form
mrna
singl
gene
target
prevent
spliceregulatori
protein
bind
effici
method
morpholino
chang
pattern
rna
splice
therefor
chang
sequenc
matur
mrna
splice
modif
might
produc
mrna
express
alter
protein
protein
might
retain
activ
might
still
bind
antibodi
would
also
bind
unalt
protein
immunochem
techniqu
use
detect
knockdown
translat
block
morpholino
often
work
use
detect
activ
splicemodifi
morpholino
activ
splicemodifi
oligo
typic
assay
rtpcr
primer
bind
either
side
alter
sequenc
alter
splice
leav
downstream
sequenc
infram
rtpcr
product
appear
differ
locat
electrophoret
gel
activ
cryptic
splice
site
result
rtpcr
fragment
unexpect
size
alter
splice
shift
downstream
read
frame
appear
prematur
termin
codon
often
result
nonsensemedi
decay
modifi
rna
wildsplic
rtpcr
product
band
might
dim
electrophoret
gel
without
correspond
splicemodifi
rtpcr
product
appear
new
band
differ
posit
matur
microrna
mirna
short
strand
rna
bound
protein
complex
chang
express
gene
mechan
includ
cleav
inhibit
translat
target
rna
discuss
mirna
anim
differ
plant
target
rna
must
site
least
partial
complementari
mirna
usual
alway
target
site
mirna
mrna
mirna
form
short
stemloop
hairpin
appropri
geometri
form
newlytranscrib
rna
nucleu
hairpin
recogn
cleav
drosha
nucleas
cleav
strand
stem
leav
singlestrand
overhang
base
result
stemloop
export
cytosol
recogn
cleav
dicer
nucleas
remov
loop
also
leav
singlestrand
overhang
base
result
short
doublestrand
rna
load
onto
protein
complex
call
rnainduc
silenc
complex
risc
protein
argonaut
famili
bind
one
strand
call
guid
strand
cleav
strand
cleav
strand
dissoci
diffus
away
leav
activ
mirnarisc
complex
morpholino
bind
mirna
guid
strand
risc
prevent
guid
strand
recogn
target
mrna
morpholino
bind
immatur
rna
hairpin
prevent
drosha
releas
stemloop
rest
transcript
morpholino
bind
stemloop
prevent
dicer
cleav
loop
stem
typic
strategi
design
morpholino
bind
entir
guid
strand
sequenc
around
base
slightli
loop
sequenc
allow
inhibit
matur
mirna
activ
risc
inhibit
mirna
matur
block
dicer
anoth
option
protect
mrna
target
bind
complementari
mirna
morpholino
block
risc
access
mrna
thu
reliev
translat
mrna
inhibit
mirna
protect
mrna
cleavag
mirnadirect
argonaut
activ
advantag
target
protect
express
target
gene
alter
inhibit
matur
activ
mirna
alter
express
mani
mrna
ppmo
coval
conjug
morpholino
oligo
cellpenetr
peptid
peptid
may
attach
end
morpholino
oligo
success
cellpenetr
peptid
contain
arginin
residu
peptid
may
compos
alpha
amino
acid
common
natur
protein
may
contain
amino
acid
acid
cellpenetr
peptid
sequenc
discuss
section
includ
rxr
b
rxr
xb
rxrrbr
xband
rx
b
dash
peptid
carboxi
terminu
repres
link
morpholino
oligo
structur
r
arginin
larginin
unless
otherwis
note
b
x
acid
chiral
amino
acid
may
l
form
form
chosen
resist
proteolyt
degrad
two
termin
arginin
peptid
dr
r
qr
k
rf
c
procedur
solutionphas
conjug
morpholino
antisens
oligo
argininerich
peptid
publish
literatur
ppmo
therapeut
applic
review
recent
section
focu
ppmo
paper
publish
sinc
review
prepar
especi
seek
efficaci
comparison
unmodifi
morpholino
ppmo
assess
toxic
immunogen
ppmo
mani
sequenc
cellpenetr
peptid
report
paper
discuss
effect
peptid
detail
structureact
comparison
refer
primari
paper
set
cellpenetr
peptid
attach
end
morpholino
target
mutant
splice
site
human
administ
mice
carri
transgen
egfp
interrupt
aberrantlyspl
human
mutant
intron
administr
differ
peptid
result
differ
biodistribut
cellpenetr
peptid
rxrrbr
xbwa
effect
correct
splice
heart
diaphragm
quadricep
import
target
muscl
duchenn
muscular
dystrophi
dmd
treatment
caus
toxic
mgkg
daili
four
day
select
intens
studi
ppmo
also
modifi
splice
smooth
muscl
gut
determin
persist
effect
mgkg
daili
four
day
rxrrbr
xbppmo
target
administ
group
mice
mice
sacrif
assess
period
week
shown
rtpcr
cardiac
muscl
one
day
final
inject
transcript
splicecorrect
decreas
splice
correct
six
week
diaphragm
splice
correct
decreas
week
treatment
week
quadricep
splice
still
correct
week
duchenn
muscular
dystrophi
dmd
aris
mutat
human
dystrophin
gene
potenti
treatment
diseas
use
stericblock
oligo
redirect
splice
skip
exon
remov
earli
stop
codon
correct
read
frame
disrupt
frameshift
mutat
sever
mous
model
dmd
develop
first
popular
mdx
mous
prematur
stop
codon
exon
unmodifi
morpholino
antisens
current
clinic
trial
dmd
howev
unmodifi
morpholino
enter
heart
effect
concentr
affect
dystrophin
splice
even
repeat
dose
high
mgkg
mdx
mice
three
paper
review
measur
mrna
exon
skip
dystrophin
concentr
system
deliveri
ppmo
mdx
mice
summar
tabl
ppmo
rxrrbr
xbpeptid
conjug
end
morpholino
sequenc
design
caus
splicemedi
excis
dystrophin
exon
inject
iv
mdx
mice
mgkg
daili
four
day
rtpcr
rna
heart
tissu
found
dystrophin
mrna
lack
exon
one
day
last
treatment
decreas
two
week
seven
week
nine
week
treatment
exon
mrna
still
detect
diaphragm
quadricep
almost
complet
skip
exon
persist
nine
week
ingel
immunostain
reveal
heart
normal
dystrophin
level
reach
week
remain
seven
week
treatment
diaphragm
quadricep
normal
dystrophin
remain
week
treatment
ppmo
rxrrbr
xbpeptid
morpholino
target
dystrophin
exon
mdx
mous
compar
unmodifi
morpholino
sequenc
either
morpholino
ppmo
inject
im
mgkg
tibiali
anterior
ta
adult
mdx
mice
ppmo
induc
strong
dystrophin
express
fiber
ta
morpholino
induc
dystrophin
express
ta
fiber
heart
dystrophin
posttreat
skelet
muscl
dystrophin
posttreat
percent
protein
mrna
compar
wildtyp
muscl
singl
retroorbit
iv
inject
mgkg
ppmo
administ
mdx
mice
dystrophin
express
assess
two
week
later
similar
inject
unmodifi
morpholino
induc
dystrophin
express
skelet
muscl
fiber
ppmo
induc
strong
dystrophin
express
skelet
muscl
fiber
nearnorm
dystrophin
level
found
western
blot
rtpcr
ppmotreat
mice
show
dystrophin
transcript
skelet
muscl
miss
exon
demonstr
ppmo
activ
unmodifi
morpholino
induc
detect
dystrophin
express
cardiac
muscl
fiber
ppmo
induc
dystrophin
express
cardiac
muscl
fiber
normal
dystrophin
level
found
western
blot
rtpcr
reveal
dystrophin
transcript
cardiac
muscl
miss
exon
assess
longerterm
treatment
mdx
mice
iv
inject
retroorbit
ppmo
mgkg
everi
two
week
three
month
total
six
inject
per
mous
two
week
last
inject
dystrophin
found
muscl
fiber
includ
smooth
muscl
small
intestin
dystrophin
level
resembl
normal
mous
tissu
cardiac
muscl
exon
skip
improv
dose
regimen
dystrophin
mrna
lack
exon
strong
dystrophin
protein
express
compar
normal
heart
damag
kidney
liver
detect
histolog
exam
ppmo
treatment
alkalin
phosphatas
creatinin
alter
ppmo
treatment
inflammatori
cell
accumul
muscl
antibodi
reactiv
ppmo
found
serum
indic
ppmo
immunogen
singl
tail
vein
inject
mgkg
ppmo
peptid
sequenc
rxr
xband
morpholino
sequenc
design
caus
excis
exon
administ
mdx
mice
three
week
later
skelet
muscl
immunostain
show
near
normal
level
dystrophin
muscl
analyz
western
blot
analysi
found
dystrophin
concentr
rang
normal
skelet
muscl
rtpcr
reveal
almost
total
skip
exon
skelet
muscl
analyz
heart
muscl
rtpcr
show
dystrophin
transcript
lost
exon
immunostain
reveal
dystrophinposit
fiber
wide
distribut
western
blot
dystrophin
concentr
normal
level
heart
found
ppmo
cellpenetr
peptid
rxr
xband
rxrrbr
xbwere
inject
iv
efficaci
compar
deliv
antisens
activ
skelet
cardiac
muscl
rxr
xbdid
effect
detect
toxic
analysi
histolog
liver
kidney
assay
serum
compon
perform
sampl
mdx
mice
treat
mgkg
ppmo
overt
sign
tissu
damag
kidney
liver
reveal
haematoxylin
eosin
stain
tissu
chang
number
infiltr
cell
compar
untreat
mdx
mice
ppmo
treat
mice
level
aspart
aminotransferas
ast
alanin
aminotransferas
alt
went
level
typic
mdx
mice
level
typic
normal
control
mice
serum
level
urea
creatinin
chang
ppmo
treatment
weekli
mgkg
tail
vein
inject
ppmo
three
week
result
less
exon
skip
singl
mgkg
tail
vein
inject
clearest
decreas
efficaci
diaphragm
abdomin
wall
muscl
heart
common
inherit
genet
diseas
human
abil
ppmo
redirect
splice
specif
splice
mutant
human
assess
heterozyg
knockin
mice
two
adult
murin
gene
deactiv
studi
use
cellpenetr
peptid
dr
r
qr
k
rf
ccoval
link
morpholino
target
aberr
splice
site
creat
mutat
c
block
splice
site
restor
normal
splice
transcript
bear
c
mutat
mice
treat
mgkg
inject
daili
inject
four
day
follow
three
rest
day
cycl
repeat
experi
termin
day
signific
liver
kidney
toxic
detect
ppmotreat
mice
compar
salinetr
mice
standard
biochem
test
ast
alt
bun
crea
signific
weight
loss
inflammatori
respons
assess
rtqpcr
cytokin
signific
chang
detect
express
compar
salineinject
ppmoinject
mice
treatment
mice
boost
ppmo
month
initi
prime
dose
ppmo
result
respons
assess
immunoassay
sera
day
boost
remain
sera
day
boost
test
elisa
antibodi
cellpenetr
peptid
antibodi
detect
lymphocyt
mice
treat
month
earlier
either
salin
ppmo
cultur
ex
vivo
challeng
ppmo
test
induct
antibodi
cellpenetr
peptid
neither
respons
detect
level
restor
theoret
achiev
experiment
condit
fairli
low
first
mice
heterozyg
human
knockin
human
hemoglobin
could
restor
normal
concentr
human
gene
durat
experi
day
murin
erythrocyt
normal
resid
blood
day
maximum
erythrocyt
could
replac
end
experi
combin
express
human
heterozygot
fraction
hemoglobin
contain
human
theoret
achiev
end
experi
drop
level
chimer
mousehuman
hemoglobin
reach
total
hemoglobin
treat
mice
day
typic
highest
antivir
efficaci
achiev
preinfect
administr
ppmo
follow
seri
postinfect
dose
recent
studi
explicitli
compar
effect
unmodifi
morpholino
oligo
ppmo
show
ppmo
far
effect
vivo
viral
applic
ppmo
recent
review
recent
paper
appli
ppmo
inhibit
virus
consid
ppmo
studi
use
rxr
bcellpenetr
peptid
moieti
efficaci
morpholino
ppmo
target
dengu
viru
test
vero
cell
mice
oligo
target
termin
nucleotid
cycliz
sequenc
test
along
scramblesequ
control
oligo
ppmo
morpholino
sequenc
rang
base
prepar
test
vero
cell
viru
ppmo
morpholino
compon
base
length
effect
decreas
viral
titer
effect
oligo
length
ppmo
uptak
test
flow
cytometri
cell
treat
ppmo
base
length
bear
fluoresc
label
effect
length
uptak
shown
ppmo
length
test
enter
cell
toxicolog
pharmacokinet
studi
ppmo
includ
studi
antivir
efficaci
morpholino
ppmo
dengu
viru
dose
regimen
test
toxic
mice
use
separ
mice
assess
dengu
inhibit
pharmacokinet
measur
addit
toxic
test
done
use
balbc
mice
mice
treat
ip
inject
daili
dose
scramblesequ
morpholino
oligo
mgkg
scramblesequ
ppmo
mgkg
two
day
follow
monitor
day
ill
effect
observ
anim
maintain
weight
dose
regimen
use
oligo
sequenc
target
dengu
viru
two
oligo
dose
mice
infect
pfu
ngc
treatment
ppmo
extend
averag
surviv
eight
day
treatment
ppmo
extend
averag
surviv
five
day
compar
control
mice
similarli
infect
treat
pb
averag
nine
day
surviv
surviv
benefit
mice
treat
unmodifi
morpholino
oligo
target
either
morpholino
ppmo
scramblesequ
treatment
determin
toxic
longer
dose
regimen
mice
treat
mgkg
daili
ip
inject
nine
day
compar
group
receiv
similar
pb
inject
anim
increas
mass
averag
g
studi
regardless
treatment
arm
anim
maintain
similar
weight
experi
repeat
pfu
dengu
infect
second
third
oligo
dose
treatment
combin
extend
life
eight
day
averag
treatment
extend
life
seven
day
averag
treatment
extend
life
statist
signific
period
compar
day
surviv
pbstreat
infect
control
balbc
mice
treat
fluoresceinconjug
ppmo
intraperiton
dose
mgkg
pharmacokinet
biodistribut
brain
liver
spleen
determin
measur
hour
peak
plasma
concentr
mgl
distribut
halflif
h
elimin
halflif
h
determin
liver
accumul
ppmofl
rapidli
brain
accumul
least
toxic
balbc
mice
address
nine
dose
regimen
daili
ip
inject
mgkg
fluorescein
ppmo
anim
appear
behav
normal
nineday
dose
fiveday
washout
period
signific
increas
serum
cholesterol
decreas
haematocrit
haemoglobin
pack
cell
volum
red
blood
cell
count
observ
treatment
return
level
similar
control
mice
washout
period
total
bilirubin
increas
treatment
treatment
like
inhibit
red
blood
cell
product
instead
increas
red
blood
cell
lysi
concentr
fluorescein
ppmo
liver
spleen
chang
significantli
washout
period
demonstr
good
retent
tissu
uptak
studi
use
oligo
complementari
ebola
zair
viru
transcript
compar
unmodifi
morpholino
ppmo
differ
class
modifi
morpholino
bear
cation
moieti
phosphorodiamid
linkag
pmo
ppmo
studi
use
sever
cellpenetr
peptid
moieti
includ
rxr
xb
rx
band
rb
b
ppmo
shown
higher
efficaci
pmo
unmodifi
morpholino
ebola
viru
test
cell
free
translat
system
vero
cell
cultur
mice
unmodifi
morpholino
sequenc
block
translat
cellfre
translat
system
gener
limit
efficaci
cell
cultur
mice
vero
cell
pretreat
oligo
two
hour
infect
gfpexpress
zair
ebola
viru
hour
cell
fix
observ
fluoresc
uninfect
cell
littl
autofluoresc
infect
untreat
cell
infect
cell
pretreat
bare
morpholino
clearli
fluoresc
infect
cell
pretreat
ppmo
reduc
fluoresc
ppmo
peptid
conjug
oligo
end
reduc
fluoresc
effect
ppmo
peptid
attach
end
morpholino
moieti
three
differ
cellpenetr
peptid
tri
link
end
end
morpholino
ppmo
cellpenetr
peptid
inhibit
viral
replic
compar
infect
cell
treat
unmodifi
morpholino
mice
treat
twice
ppmo
rx
bpeptid
conjug
morpholino
target
end
transcript
mice
inject
hour
prior
four
hour
prior
infect
ebola
viru
lethal
challeng
pfu
ebola
viru
deliv
ip
mice
track
day
ppmo
rx
bpeptid
conjug
end
morpholino
effect
treatment
dose
kept
treat
mice
aliv
dose
save
mice
test
similar
experi
pretreat
hour
prior
four
hour
prior
infect
pfu
ebola
viru
ip
ppmo
construct
fewer
rx
repeat
effect
protect
mice
ebola
challeng
unmodifi
morpholino
prevent
death
mice
use
experi
per
inject
similar
experi
use
ppmo
rx
bpeptid
conjug
morpholino
target
start
codon
transcript
gave
protect
per
dose
protect
per
dose
oligo
conjug
end
gave
protect
per
dose
protect
per
dose
oligo
conjug
end
experi
unmodifi
morpholino
gave
protect
per
dose
morpholino
conjug
rxr
xbcellpenetr
peptid
administ
intranas
balbc
mice
inhibit
viral
replic
one
oligo
target
start
site
viral
polymeras
subunit
mrna
anoth
target
end
np
virion
rna
prepar
unmodifi
morpholino
ppmo
intranas
deliveri
lung
tissu
shown
effect
use
scrambledsequ
ppmo
conjug
fluorescein
deliveri
lung
shown
best
upper
lung
closest
major
bronchiol
decreas
middl
lower
lung
toxic
test
perform
treatment
mgkg
administ
intranas
hour
later
compar
salinetr
mice
ppmotreat
mice
show
signific
weight
loss
assess
daili
weigh
hour
follow
first
dose
observ
ill
signific
differ
note
histopatholog
examin
lung
tissu
compar
salinetr
mice
leukocyt
popul
spleen
lung
follow
flow
cytometr
analysi
signific
chang
spleen
popul
found
lung
popul
differ
significantli
highest
dose
per
administr
mgkg
signific
differ
dose
mgkg
less
mgkg
dose
macrophag
increas
fold
granulocyt
increas
fold
author
suggest
argininerich
cellpenetr
peptid
may
caus
leukocyt
infiltr
mimick
known
effect
polyarginin
trigger
respons
similar
major
basic
protein
compon
granul
eosinophil
test
antivir
activ
mice
dose
intranas
mixtur
two
ppmo
mgkg
dose
administ
four
hour
hour
infect
influenza
viru
mice
compar
mice
dose
similarli
unmodifi
morpholino
morpholino
ppmo
scrambl
sequenc
control
salin
lung
tissu
taken
hour
infect
plaqu
assay
mix
ppmo
shown
reduc
viral
growth
log
compar
scrambl
ppmo
mix
unmodifi
morpholino
caus
slight
signific
decreas
viral
titer
compar
scrambl
morpholino
test
compar
preinfect
treatment
versu
postinfect
treatment
show
clear
benefit
pretreat
though
smaller
still
signific
decreas
viral
titer
occur
treatment
delay
hr
hr
postinfect
global
therapeut
cardiolog
unit
cook
medic
http
wwwcookmedicalcom
develop
ppmocoat
stent
balloon
angioplasti
use
ppmo
avi
biopharma
inc
morpholino
moieti
target
cmyc
inhibit
prolifer
vascular
endotheli
cell
might
otherwis
caus
restenosi
vivomorpholino
morpholino
oligo
coupl
eight
guanidinium
head
group
dendrim
scaffold
enabl
deliveri
cell
other
demonstr
like
ppmo
vivomorpholino
extend
proven
morpholino
antisens
technolog
research
adult
anim
potent
antisens
effect
observ
wide
rang
tissu
anim
inject
vivomorpholino
dosag
produc
detect
toxic
vivomorpholino
use
success
variou
adult
anim
includ
healthi
mice
mous
model
duchenn
muscular
dystrophi
dog
model
duchenn
muscular
dystrophi
toshifumi
yokota
person
commun
vivomorpholino
provid
power
tool
gene
regul
studi
anim
effici
synthesi
design
highthroughput
product
protocol
morpholino
oligom
wide
use
modul
gene
express
cell
cultur
embryo
zebrafish
frog
tunic
chick
sea
urchin
activ
unmodifi
morpholino
oligo
adult
anim
report
primarili
leaki
tissu
damag
muscl
anim
model
dmd
howev
deliveri
effici
highli
variabl
within
tissu
ineffici
tissu
includ
heart
diaphragm
muscl
vivomorpholino
improv
deliveri
blood
cytosol
nuclei
dystroph
mice
fold
compar
unmodifi
morpholino
enter
muscl
due
leaki
characterist
dmd
muscl
addit
antisens
effect
vivomorpholino
achiev
evenli
effici
bodywid
tissu
includ
heart
diaphragm
smooth
muscl
healthi
adult
anim
iv
treatment
unmodifi
morpholino
oligom
caus
antisens
activ
cell
recent
studi
shown
vivomorpholino
achiev
deliveri
wide
varieti
tissu
normal
adult
mice
detect
deliveri
unmodifi
morpholino
achiev
dosag
summari
vivomorpholino
exhibit
significantli
higher
deliveri
effici
adult
anim
unmodifi
morpholino
efficaci
antisens
effect
mediat
vivomorpholino
test
healthi
adult
mice
dmd
diseas
mous
model
leaki
muscl
vivomorpholino
test
adult
mice
intact
cell
membran
bear
transgen
mutat
prevent
product
enhanc
green
fluoresc
protein
egfp
error
could
correct
redirect
splice
vivomorpholino
oligo
result
express
egfp
recent
studi
demonstr
vivomorpholino
effici
correct
error
variou
tissu
egfp
transgen
mice
show
detect
toxic
mdx
mous
model
dmd
vivomorpholino
shown
potent
antisens
effect
bodywid
muscl
includ
hardtodeliv
heart
diaphragm
muscl
vivomorpholino
test
local
inject
dmd
diseas
dog
model
exhibit
similar
potenc
local
inject
mdx
mice
toshifumi
yokota
person
commun
differ
rout
inject
result
variou
biodistribut
vivomorpholino
tissu
local
system
deliveri
method
test
adult
mice
tabl
intraven
iv
liver
small
intestin
colon
skelet
muscl
spleen
lung
heart
skin
stomach
kidney
brain
subcutan
sc
inject
mainli
effect
target
skin
fail
deliv
muscl
heart
jiang
et
al
manuscript
prepar
intramuscular
im
inject
effici
deliv
vivomorpholino
muscl
near
inject
site
tissu
includ
heart
brain
diaphragm
intraperiton
ip
inject
effici
rout
deliv
vivomorpholino
diaphragm
abdomin
muscl
intraven
iv
inject
system
deliveri
achiev
tissu
includ
liver
small
intestin
colon
skelet
muscl
spleen
lung
heart
skin
stomach
kidney
brain
antisens
efficaci
vivomorpholino
demonstr
sever
duchenn
muscular
dystrophi
dmd
diseas
anim
model
recent
data
suggest
efficaci
vivomorpholino
ppmo
similar
local
inject
dystroph
dog
toshifumi
yokota
person
commun
vivomorpholino
target
splice
site
dystrophin
mrna
restor
dystrophin
protein
product
mdx
mice
effici
antisens
effect
dosag
depend
vivomorpholino
exhibit
significantli
higher
impact
splicemodifi
mrna
protein
level
dose
mgkg
mgkg
singl
intraven
inject
mgkg
vivomorpholino
splice
defect
dystrophin
gene
skelet
muscl
fiber
mdx
mice
repeat
inject
mgkg
vivomorpholino
mdx
mice
biweekli
week
restor
dystrophin
protein
near
normal
level
skelet
muscl
test
includ
bicep
diaphragm
intercost
tibiali
anterior
quadricep
gastrocnemiu
abdomin
muscl
significantli
inject
vivomorpholino
achiev
cardiac
deliveri
enabl
dystrophin
protein
product
heart
assay
blood
marker
liver
toxic
ast
alt
show
chang
liver
function
signific
impact
bodi
weight
histolog
liver
kidney
importantli
potenti
therapeut
applic
multipl
inject
vivomorpholino
stimul
adapt
immun
respons
mice
determin
elisa
vivomorpholino
use
mous
serum
potent
antisens
effect
anim
lack
obviou
toxic
effect
dosag
make
vivomorpholino
good
research
reagent
modifi
gene
express
therapeut
index
long
term
toxic
must
assess
period
administr
vivomorpholino
often
requir
maintain
antisens
effect
recent
effect
use
morpholino
antisens
limit
applic
deliveri
techniqu
devis
mani
attempt
success
vivo
applic
unmodifi
morpholino
adult
anim
develop
morpholino
oligo
conjug
cellpenetr
peptid
ppmo
made
adult
anim
experi
feasibl
morpholino
clinic
develop
ppmo
stent
inhibit
restenosi
balloon
angioplasti
expect
begin
immin
ppmo
late
preclin
develop
duchenn
muscular
dystrophi
unlik
ppmo
vivomorpholino
commerci
avail
research
reagent
vivomorpholino
success
test
adult
anim
provid
investig
conveni
access
researchgrad
deliveryen
morpholino
antisens
